Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 407


The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer.

Elsaba TM, Martinez-Pomares L, Robins AR, Crook S, Seth R, Jackson D, McCart A, Silver AR, Tomlinson IP, Ilyas M.

PLoS One. 2010 May 19;5(5):e10714. doi: 10.1371/journal.pone.0010714.


Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.

Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N.

Oncol Rep. 2012 Oct;28(4):1301-8. doi: 10.3892/or.2012.1951. Epub 2012 Aug 6.


CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.

Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T, Kunz-Schughart LA.

Radiother Oncol. 2009 Sep;92(3):353-61. doi: 10.1016/j.radonc.2009.06.034. Epub 2009 Aug 21.


The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.

Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A.

J Pathol. 2009 Dec;219(4):427-34. doi: 10.1002/path.2597.


Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines.

Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH.

Ann Surg Oncol. 2011 Jun;18(6):1797-804. doi: 10.1245/s10434-011-1561-2. Epub 2011 Jan 26.


CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116.

Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T, Kunz-Schughart LA.

Radiother Oncol. 2010 Mar;94(3):375-83.


CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.

Muraro MG, Mele V, Däster S, Han J, Heberer M, Cesare Spagnoli G, Iezzi G.

Stem Cells Transl Med. 2012 Aug;1(8):592-603. doi: 10.5966/sctm.2012-0003. Epub 2012 Aug 6.


A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.

Ernst A, Aigner M, Nakata S, Engel F, Schlotter M, Kloor M, Brand K, Schmitt S, Steinert G, Rahbari N, Koch M, Radlwimmer B, Weitz J, Lichter P.

Pathology. 2011 Apr;43(3):220-7. doi: 10.1097/PAT.0b013e328344e391.


Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.

Kim ST, Sohn I, DO IG, Jang J, Kim SH, Jung IH, Park JO, Park YS, Talasaz A, Lee J, Kim HC.

Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):259-66.


In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.

Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A, Giordano C.

PLoS One. 2008;3(10):e3544. doi: 10.1371/journal.pone.0003544. Epub 2008 Oct 28.


Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.

Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, Ichihara E, Yamane H, Tanimoto M, Kiura K.

Cancer Sci. 2013 Jan;104(1):78-84. doi: 10.1111/cas.12045. Epub 2012 Nov 24.


Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.

Jing F, Kim HJ, Kim CH, Kim YJ, Lee JH, Kim HR.

Int J Oncol. 2015 Apr;46(4):1582-8. doi: 10.3892/ijo.2015.2844. Epub 2015 Jan 23.


Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo.

Peickert S, Waurig J, Dittfeld C, Dietrich A, Garbe Y, Kabus L, Baumann M, Grade M, Ried T, Kunz-Schughart LA.

Lab Invest. 2012 Nov;92(11):1607-22. doi: 10.1038/labinvest.2012.124. Epub 2012 Sep 10.


Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells.

Yusra, Semba S, Yokozaki H.

Int J Oncol. 2012 Jul;41(1):201-10. doi: 10.3892/ijo.2012.1459. Epub 2012 May 2.


Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.

Wang D, Fu L, Sun H, Guo L, DuBois RN.

Gastroenterology. 2015 Dec;149(7):1884-1895.e4. doi: 10.1053/j.gastro.2015.07.064. Epub 2015 Aug 7.


Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.

Yang Z, Zhang L, Ma A, Liu L, Li J, Gu J, Liu Y.

PLoS One. 2011;6(12):e28405. doi: 10.1371/journal.pone.0028405. Epub 2011 Dec 1.


Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.

Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW, Cho EJ, Han JW.

Cell Death Dis. 2015 Nov 5;6:e1964. doi: 10.1038/cddis.2015.313.


CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers.

Chen J, Guo T, Zhang L, Qin LX, Singer S, Maki RG, Taguchi T, Dematteo R, Besmer P, Antonescu CR.

Genes Chromosomes Cancer. 2012 Feb;51(2):186-95. doi: 10.1002/gcc.20942. Epub 2011 Nov 10.


Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells.

Xue ZX, Zheng JH, Zheng ZQ, Cai JL, Ye XH, Wang C, Sun WJ, Zhou X, Lu MD, Li PH, Cai ZZ.

World J Surg Oncol. 2014 Dec 30;12:404. doi: 10.1186/1477-7819-12-404.


Proteomic profiling of tumor-initiating cells in HT-29 human colorectal cancer cells.

Lee HN, Park SH, Lee EK, Bernardo R, Kim CW.

Biochem Biophys Res Commun. 2012 Oct 12;427(1):171-7. doi: 10.1016/j.bbrc.2012.09.036. Epub 2012 Sep 17.


Supplemental Content

Support Center